Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Gauthier

Showing results (131-140 of 135) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 135 results.
Bioorganic & Medicinal Chemistry Letters|December 29, 2000
Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx)D A Nicoll-Griffith, J A Yergey, L A Trimble, et al.
Pigment Cell & Melanoma Research|March 16, 2012
Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus ConferenceK Ezzedine, H W Lim, T Suzuki, et al.
The British Journal of Dermatology|August 7, 2012
Guidelines for the management of vitiligo: the European Dermatology Forum consensusA Taieb, A Alomar, M Böhm, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profilesC C Chan, S Boyce, C Brideau, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.
Pageof 14

Showing results (131-140 of 135) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 135 results.
Bioorganic & Medicinal Chemistry Letters|December 29, 2000
Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx)D A Nicoll-Griffith, J A Yergey, L A Trimble, et al.
Pigment Cell & Melanoma Research|March 16, 2012
Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus ConferenceK Ezzedine, H W Lim, T Suzuki, et al.
The British Journal of Dermatology|August 7, 2012
Guidelines for the management of vitiligo: the European Dermatology Forum consensusA Taieb, A Alomar, M Böhm, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profilesC C Chan, S Boyce, C Brideau, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.
Pageof 14